GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Nice to see the volume picking up. With the tiny amount of stock the mm's will have no choice soon but to take it up regardless of news.
If this was on the american markets.....It would be flying. UK markets are such a drag and boring. Gone are the days of the companies that use to rip before the news.
Tiger - the whole FTSE and AIM especially is as unloved as it’s possible to be at the moment. Investors are few and far between and traders are only interested in the flavour of the moment. Such abnormal conditions produce superb potential returns. We are fortunate in that respect.
This is no doubt a great company with serious potential , i just dont get why the SP is still so low .... anyone ???
And I should add is now part of Abbott
St Jude is already a customer of Rua since elasteon is used on other products of theirs
Apart from Edwards Lifesciences $54B, there is also Medtronic $106B, St Jude $25B Boston Scientific $109B and tiddler Livanova at just $2.9B .... all in the Heart Valve / Cardiac Technology space
Be nice to think there could be more than one looking at Elast-EON...... Deep pocket bidding war....or is that just a dream?
Buys now going through at the full ask 13.5p. It would be nice to break 15p with no news!!!
Live prices 12.56 sell 13.11 buy - for normal trade volume
I agree it is a hidden gem. Couldn't agree more that the stocks to look for are those with no funding needs and either in profitability or moving towards profitable status.
With RUA there is the bonus of diversity and four separate businesses with two of the four 'strands' already profitable and a potential licensing deal or even a takeover with the 'partner' (I assume Edwards) as they reference the global Heart Valve company if the MTA Agreement progresses to some kind of commercial outcome.
Edwards has a m/cap of $54 billion so (if they are the partner) I assume they would buy RUA rather than negotiate a licensing deal. I don't know what they would pay but I assume between £50m upwards. That's the blue sky angle but the cash held and the steady move to profitability and prudent preservation of cash makes this an appealing hold.
No doubt it's tested the patience of long-term holders and maybe more patience is needed but it's far from pie in the sky to suggest that the end result could be a share price of around 80p to 100p or circa £50m to £60m m/cap.
Looking at trades (I don't pay much attention) there seems to be more large purchases than normal. Looking positive.
Looks likely
NT. at 13p at Lloyds.
Is it going to break 13p this time
Morning all. Jimzi - very helpful posts. IIs certainly want their pound of flesh to fund placings. Been burnt by Avacta, GST, and CPX. It’s not an easy market out there. This share is a hidden gem.
Nice buys
Jeez, just seen polx raise - at 1p. It’s great tech ( but has a hell of long sales lead time) but what a discount.
That’s why many of us impress on the bb the 4 year cash safety net. It’s bloody invaluable in this market- and still peeps sell at 11p. What a fooked up market all round . When you see the best risk reward share on AIM, just sit on your holdings 👈🏻
Does anyone know who took the £3m institution placing? Reatal offer was only £1m.
Looks like the traders are doing their thing. Such is life and “it adds liquidity”. I’d rather see them bale down here and be gone before the big news breaks.
Buys now starting to come in, 12.5p to be tested. Hopefully the patient holders will be rewarded. Good luck all. Atb Popeye.
Looks like it's going to pop again but this time at much higher prices of 12.5p rather than 11p at the start of the week. More they rise the more momentum players get involved
Indeed - a large contract win for contract manufacturing changes not just the business case but the sentiment too. Could be a huge catalyst once the short termists are cleared out.
Just for clarity the trades at 11.45 were buys.
The current mcap [ex cash of £4m] is £3m.
They are not just a one trick pony.
- core business growing and revenues expected to double
- heart value being testing with leading partner with plans to commercialise
-VASCULAR GRAFT developed and looking to partner
No placing for years and NO WARRANTS..
60m shares.
Cash Position
Strong cost management, together with the anticipated recovery in trading during the second half, means the Company remains financially resilient, with a strong balance sheet and a cash position of approximately £4.0m. Despite challenging trading conditions, these achievements underscore the Group's resilience and adeptness in financial and operational management.
Before this statement there was £2.2m rev and costs £3.1m. So its poss the co may become profitable at the end of the year.
Profitable life sciences at EV£3m do not exist - multiple earning valuations kick in so this is not a one rev co